Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle. Icosavax is a member of the AstraZeneca Group.
View Top Employees from Icosavax, Inc.Website | http://www.astrazeneca.com |
Employees | 65 (65 on RocketReach) |
Founded | 2018 |
Address | 1930 Boren Ave Suite 1000, Seattle, Washington 98101, US |
Technologies |
JavaScript,
HTML,
PHP
+29 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Vaccine Development, Science and Engineering, Discovery Tools (Healthcare), Infectious Disease, Health Care, VLPs, RSV, Respiratory syncytial virus, Vaccines, Vaccine |
Looking for a particular Icosavax, Inc. employee's phone or email?
Adam Simpson is the Chief Executive Officer and Co-Founder of Icosavax, Inc..
65 people are employed at Icosavax, Inc..
Icosavax, Inc. is based in Seattle, Washington.